NCT00374803View on ClinicalTrials.gov

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
End Stage Renal Disease (ESRD)
Interventions
DRUG

Mycophenolic Acid (Myfortic)

"* Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."

Trial Locations (2)

45267

The Christ Hospital, Cincinnati

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Cincinnati

OTHER